{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:59:12Z","timestamp":1791262752111,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteogenesis imperfecta (OI) is a heterogeneous type 1 collagenopathy characterized by recurrent fractures, decreased bone mass, and short stature. Bisphosphonates reduce fracture incidence in children with OI, but do not improve growth velocity. C-type natriuretic peptide (CNP) is produced in the growth plate (also in the brain and heart), and it positively regulates linear bone growth; people with OI have been shown to have reduced serum levels of CNP. This pilot study evaluated whether a CNP analog combined with alendronate (ALN) improves growth and BMD in oim\/oim (OIM) mice, a model of moderate-to-severe Type III OI. Two-wk-old OIM and WT mice received weekly ALN and 1 of 3 CNP regimens: 10\u00a0\u03bcg\/kg 3 d\/wk (low), 20\u00a0\u03bcg\/kg 3 d\/wk (medium), or 20\u00a0\u03bcg\/kg 5 d\/wk (high). Controls received saline. Faxitron images were taken at 2, 8, and 14 wk (sacrifice) to assess fracture incidence and measure femoral length and vertebral height. MicroCT was used to assess bone microstructural parameters of the femur ex vivo. The high-dose group had no fractures post-sacrifice, while 1 fracture each was observed in the low and medium dose groups. Femoral length increased in all treated groups, with the high dose-group showing the greatest increase (8.2% and significant) in OIM mice. Vertebral height increased in all treated groups; low and high dose groups had greater and comparable increases than the medium group in OIM mice. All treated groups showed increased trabecular BMD. Cortical tissue mineral density, BMD, and thickness were also elevated in all treated groups compared to the controls. In conclusion, CNP analog adjuvant treatment enhanced linear growth and bone quality without compromising fracture reduction, providing benefits not seen with bisphosphonates alone. These results will inform optimal dosing for future studies. A full murine study is planned to further evaluate the therapeutic potential for translation to humans.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf190","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:11:18Z","timestamp":1765372278000},"page":"762-771","source":"Crossref","is-referenced-by-count":0,"title":["Combined treatment with a C-type natriuretic peptide analog and bisphosphonate enhances bone growth in growing mice with osteogenesis imperfecta: a pilot study"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5058-1223","authenticated-orcid":false,"given":"Jack E","family":"Mulcrone","sequence":"first","affiliation":[{"name":"Hospital for Special Surgery , HSS Research Institute, New York, NY 10021 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketsia","family":"Seide","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery , HSS Research Institute, New York, NY 10021 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chacko","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery , HSS Research Institute, New York, NY 10021 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8754-6354","authenticated-orcid":false,"given":"Erin M","family":"Carter","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery , HSS Research Institute, New York, NY 10021 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Pleshko","sequence":"additional","affiliation":[{"name":"Temple University , Department of Bioengineering, Philadelphia, PA 19122 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7333-9859","authenticated-orcid":false,"given":"Chloe E","family":"Derocher","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery , HSS Research Institute, New York, NY 10021 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathleen L","family":"Raggio","sequence":"additional","affiliation":[{"name":"Hospital for Special Surgery , HSS Research Institute, New York, NY 10021 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"9418","key":"2026081703265800500_ref1","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"2026081703265800500_ref18","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment","volume":"164","author":"Van Dijk","year":"2014","journal-title":"Am J Med Genet"},{"key":"2026081703265800500_ref2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"issue":"6","key":"2026081703265800500_ref3","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","article-title":"Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment","volume":"164","author":"Van Dijk","year":"2014","journal-title":"Am J Med Genet"},{"key":"2026081703265800500_ref7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bone.2018.07.026","article-title":"Siglec-15-targeting therapy increases bone mass in rats without impairing skeletal growth","volume":"116","author":"Sato","year":"2018","journal-title":"N Bone"},{"issue":"2","key":"2026081703265800500_ref4","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1542\/peds.2006-2023I","article-title":"Experience with bisphosphonates in osteogenesis imperfecta","volume":"119","author":"Glorieux","year":"2007","journal-title":"Pediatrics"},{"key":"2026081703265800500_ref13","first-page":"367","article-title":"Current and emerging treatments for the management of osteogenesis imperfecta","volume":"6","author":"Monti","year":"2010","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"2026081703265800500_ref5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1073\/pnas.96.1.133","article-title":"Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro","volume":"96","author":"Fisher","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"2026081703265800500_ref17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"issue":"5","key":"2026081703265800500_ref15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1203\/00006450-200211000-00010","article-title":"Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model","volume":"52","author":"Mccarthy","year":"2002","journal-title":"Pediatr Res"},{"key":"2026081703265800500_ref21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/bonekey.2014.24","article-title":"Bisphosphonates and bone quality","volume":"3","author":"Pazianas","year":"2014","journal-title":"Bonekey Rep"},{"issue":"4","key":"2026081703265800500_ref22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/1759720X13485829","article-title":"Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions","volume":"5","author":"Ruza","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026081703265800500_ref8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s002230010045","article-title":"A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta","volume":"69","author":"Camacho","year":"2001","journal-title":"Calcif Tissue Int"},{"issue":"21","key":"2026081703265800500_ref14","doi-asserted-by":"publisher","first-page":"e171984","DOI":"10.1172\/jci.insight.171984","article-title":"Altered Sox9 and FGF signaling gene expression in Aga2 OI mice negatively affects linear growth","volume":"8","author":"Zieba","year":"2023","journal-title":"JCI Insight"},{"key":"2026081703265800500_ref28","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41390-023-02550-0","article-title":"Standardized growth charts for children with osteogenesis imperfecta","volume":"94","author":"Robinson","year":"2023","journal-title":"Pediatr Res"},{"issue":"2","key":"2026081703265800500_ref29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41436-018-0045-1","article-title":"Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study","volume":"21","author":"Jain","year":"2018","journal-title":"Genetics in Medicine"},{"key":"2026081703265800500_ref16","doi-asserted-by":"publisher","first-page":"115547","DOI":"10.1016\/j.bone.2020.115547","article-title":"Assessment of longitudinal bone growth in osteogenesis imperfecta using metacarpophalangeal pattern profiles","volume":"140","author":"Rauch","year":"2020","journal-title":"Bone."},{"issue":"4","key":"2026081703265800500_ref6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"2026081703265800500_ref12","doi-asserted-by":"publisher","first-page":"E355","DOI":"10.1210\/jc.2014-2814","article-title":"C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia","volume":"100","author":"Olney","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026081703265800500_ref23","doi-asserted-by":"publisher","first-page":"bqac005","DOI":"10.1210\/endocr\/bqac005","article-title":"C-type natriuretic peptide-induced PKA activation promotes endochondral bone formation in hypertrophic chondrocytes","volume":"163","author":"Hirota","year":"2022","journal-title":"Endocrinology."},{"issue":"37","key":"2026081703265800500_ref25","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.2174\/138161210794519237","article-title":"C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target","volume":"16","author":"Lumsden","year":"2010","journal-title":"Curr Pharm Des"},{"key":"2026081703265800500_ref30","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf085","article-title":"C-type natriuretic peptide (CNP) and collagen X marker (CXM) are aberrant in skeletal dysplasias","author":"Carroll","year":"2025","journal-title":"J Bone Miner Res"},{"key":"2026081703265800500_ref11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","article-title":"C-type natriuretic peptide analogue therapy in children with achondroplasia","volume":"381","author":"Savarirayan","year":"2019","journal-title":"N Engl J Med"},{"key":"2026081703265800500_ref24","author":"Wend","year":"2016"},{"issue":"15","key":"2026081703265800500_ref9","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/j.biomaterials.2006.11.043","article-title":"FT-IR imaging of native and tissue-engineered bone and cartilage","volume":"28","author":"Boskey","year":"2007","journal-title":"Biomaterials"},{"key":"2026081703265800500_ref10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.biomaterials.2006.11.043","article-title":"FT-IR imaging of native and tissue-engineered bone and cartilage","volume":"10","author":"Boskey","year":"2005","journal-title":"J Biomed Opt"},{"issue":"1","key":"2026081703265800500_ref31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41413-024-00354-4","article-title":"SREBP2 restricts osteoclast differentiation and activity by regulating IRF7 and limits inflammatory bone erosion","volume":"12","author":"Kim","year":"2024","journal-title":"Bone Res"},{"issue":"3","key":"2026081703265800500_ref19","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00198-011-1742-7","article-title":"Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta","volume":"23","author":"Bargman","year":"2012","journal-title":"Osteoporos Int"},{"issue":"50","key":"2026081703265800500_ref20","doi-asserted-by":"publisher","first-page":"50563","DOI":"10.1074\/jbc.M307310200","article-title":"Osteocrin, a novel bone-specific secreted protein that modulates the osteoblast phenotype","volume":"278","author":"Thomas","year":"2003","journal-title":"J Biol Chem"},{"issue":"6","key":"2026081703265800500_ref26","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","article-title":"Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia","volume":"91","author":"Lorget","year":"2012","journal-title":"Am J Hum Genet"},{"key":"2026081703265800500_ref27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1203\/00006450-200002000-00007","article-title":"Regulation of fetal rat bone growth by C-type natriuretic peptide and cGMP","volume":"47","author":"Mericq","year":"2000","journal-title":"Pediatr Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf190\/65838867\/zjaf190.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/7\/762\/65838867\/zjaf190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/7\/762\/65838867\/zjaf190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:27:02Z","timestamp":1786951622000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/7\/762\/8377249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,12,11]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf190","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2025,12,11]]}}}